The prevalence of carbohydrate metabolism disorders in patients after coronavirus infection

Introduction. A single-center observational cross-sectional comparative study was conducted among a random population sample of the adult population of the city of Moscow who applied to the pavilion "Healthy Moscow". The study included 796 patients who had a coronavirus infection from one to six months ago. Of the 796 surveyed, 112 participants had disorders of carbohydrate metabolism (hereinafter – DCM) (14.1%): 9.8% (78 people) were newly diagnosed with type 2 diabetes (D2t) of the total sample, prediabetes – 4.2% (33 people), type 1 diabetes – 0.1% (1 person). Previously diagnosed D2t was observed in 0.5% (4 participants) of the total sample of patients. Viral pneumonia was significantly more common in patients with DCM, compared with the group without DCM (45.5% vs. 19.1%, p< 0.001). In the group of lung injuries, DCM were observed with greater frequency, including D2t, the probability of which in the presence of lung damage increased by 3.7 times (95% CI: 2.04 – 6.67).
Thus, the prevalence of newly detected DCM after COVID-19 was 14.1%, and the more severe the coronavirus infection, the more likely the DCM will develop in the future.
The study was carried out as part of the project of the Department of Health of the city of Moscow "Scientific laboratory "Moscow polyclinic".

1. Dedov I.I., Shestakova M.V., Galstyan G.R. The prevalence of type 2 diabetes mellitus in the adult population of Russia (NATION study) // Diabetes mellitus. – 2016. – T. 19. – No. 2. – P. 104-112. doi: 10.14341/DM2004116-17.

2. Dedov I.I., Shestakova M.V., Vikulova O.K., et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal Registry of Diabetes Mellitus as of 01.01.2021 // Diabetes Mellitus. – 2021. – T. 24. – No. 3. – S. 204-221. doi: https://doi.org/10.14341/DM12759

3. Nesan GSCQ, Keerthana D, Yamini R, et al. 3-Month Symptom-Based Ambidirectional Follow-up Study Among Recovered COVID-19 Patients from a Tertiary Care Hospital Using Telehealth in Chennai, India. Inquiry. 2021 Jan-Dec;58:469580211060165. doi: 10.1177/00469580211060165.

4. Markova T.N., Lysenko M.A., Ponomareva A.A., et al. The prevalence of carbohydrate metabolism disorders in patients with a new coronavirus infection // Diabetes mellitus. – 2021. – T. 24. – No. 3. – S. 222-230. doi: https://doi.org/10.14341/DM12712

5. Dedov I.I., Mokrysheva N.G., Shestakova M.V., et al. Glycemic control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: consensus decision of the expert council of the Russian Association of Endocrinologists // Diabetes. – 2022 – T. 25. – No. 1. – S. 27-49. doi: https://doi.org/10.14341/DM12873

6. Yan Y, Yang Y, Wang F, et al. Clinical characteristics and outcomes of patients with severe COVID-19 with diabetes. BMJ Open Diabetes Res Care. 2020;8(1):e001343. doi:10.1136/bmjdrc-2020-00134

7. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycemia. Lancet. 2009;373(9677):1798-1807. doi:10.1016/S0140-6736(09)60553-5

8. Marik PE, Bellomo R. Stress hyperglycemia: an essential survival response! Critcare. 2013;17(2):305. doi:10.1186/cc12514

9. Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. J Med Virol. 2020;92(7):770-775. doi:10.1002/jmv.25887

10. Markova T.N., Ponomareva A.A., Samsonova I.V., et al. Risk factors for death in patients with type 2 diabetes mellitus and novel coronavirus infection. Endocrinology: news, opinions, training. 2022. V. 11, No. 1. C. 8–16. DOI: https://doi.org/10.33029/2304-9529-2022-11-1-8-16

11. Avdeev S.N., Adamyan L.V., Alekseeva E.I., et al. Temporary guidelines. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19). Ministry of Health of the Russian Federation. Version 16. 18.08.2022 Available at: https://docs.yandex.ru/docs/view?tm=1670747712&tld=ru&lang=ru&name=BMP_COVID-19_V16.pdf

12. Sathish T, Kapoor N, Cao Y, et. al. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab. 2021 Mar;23(3):870-874. doi: 10.1111/dom.14269.

13. Shestakova M.V., Kononenko I.V., Kalmykova Z.A., et al. Elevated levels of glycated hemoglobin (HbA1c) in patients with COVID-19 is a marker of the severity of the infection, but not an indicator of previous diabetes mellitus // Diabetes. – 2020. – T. 23. – No. 6. – S. 504-513. doi: https://doi.org/10.14341/DM12702

14. Arutyunov G. P., Tarlovskaya E. I., Arutyunov A. G. on behalf of a group of co-authors. Clinical features of the post-COVID period. Results of the international registry “Analysis of the dynamics of comorbid diseases in patients who have undergone infection with SARS-CoV-2 (ACTIVE SARSCoV-2)”. Preliminary data (6 months of observation). Russian journal of cardiology. 2021;26(10):4708. doi:10.15829/1560-4071-2021-470

15. Yonggang Zhou, Binqing Fu, Xiaohu Zheng, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients, National Science Review, Volume 7, Issue 6, June 2020, Pages 998–1002, https://doi.org/10.1093/nsr/nwaa041

16. Zhou W, Ye S, Wang W, et al. Clinical Features of COVID-19 Patients with Diabetes and Secondary Hyperglycemia. J Diabetes Res. 2020 Aug 24;2020:3918723. doi: 10.1155/2020/3918723.

17. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020 Mar 31:e3319. doi: 10.1002/dmrr.3319.

18. Kamal M, Abo Omirah M, Hussein A, et al. Assessment and characterization of post-COVID-19 manifestations. Int J Clin Pract. 2021 Mar;75(3):e13746. doi: 10.1111/ijcp.13746.

19. Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes Metab Syndr. 2020;14(4):513-517. doi:10.1016/j.dsx.2020.04.049